Cargando…

The Safety of Direct Oral Anticoagulants Versus Warfarin Among Older Individuals With Acute Venous Thromboembolism and CKD: A Population-Based Cohort Study

Detalles Bibliográficos
Autores principales:	Harel, Ziv, Jeyakumar, Nivethika, Luo, Bin, Silver, Samuel A., Akbari, Ayub, Molnar, Amber O., Sood, Manish M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485588/ https://www.ncbi.nlm.nih.gov/pubmed/36147201 http://dx.doi.org/10.1016/j.xkme.2022.100516

Ejemplares similares

Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2021)

Proteinuria and venous thromboembolism in pregnancy: a population-based cohort study
por: Akbari, Ayub, et al.
Publicado: (2021)

Perceived and Objective Kidney Disease Knowledge in Patients With Advanced CKD Followed in a Multidisciplinary CKD Clinic
por: Molnar, Amber O., et al.
Publicado: (2020)

Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
por: Lutsey, Pamela L., et al.
Publicado: (2019)

Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2023)

Therapeutic options for the treatment of venous thromboembolism in case of warfarin intolerance: Effects of novel oral anticoagulants
por: Kodani, Eitaro
Publicado: (2013)

Recurrent Venous Thromboembolism in a Patient with Klippel-Trenaunay Syndrome Despite Adequate Anticoagulation with Warfarin
por: Asnake, Zekarias T, et al.
Publicado: (2020)

Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study
por: Jun, Min, et al.
Publicado: (2017)

Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism
por: Kang, Hye‐Rim, et al.
Publicado: (2023)

Urinary Potassium Excretion and Progression From Advanced CKD to Kidney Failure
por: Hundemer, Gregory L., et al.
Publicado: (2022)

Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism – The SWAN Study
por: Hendriks, Thomas, et al.
Publicado: (2020)

Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis
por: Niyomsri, Siwaporn, et al.
Publicado: (2023)

New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010)

New anticoagulants for the treatment of venous thromboembolism
por: Fernandes, Caio Julio Cesar dos Santos, et al.
Publicado: (2016)

Extended anticoagulation for unprovoked venous thromboembolism
por: Castellucci, Lana A., et al.
Publicado: (2018)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism
por: Witt, Daniel M., et al.
Publicado: (2016)

Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism
por: Vandell, Alexander G, et al.
Publicado: (2017)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'
por: Klok, Frederikus A., et al.
Publicado: (2019)

Thromboprophylaxis for venous thromboembolism prevention in hip fracture patients
Publicado: (2017)

Potentially inappropriate prescribing in older adults with advanced chronic kidney disease
por: Molnar, Amber O., et al.
Publicado: (2020)

Reply to comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'
por: Jara-Palomares, Luis, et al.
Publicado: (2019)

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism
por: McRae, Simon J, et al.
Publicado: (2005)

Optimal duration of anticoagulation in patients with venous thromboembolism
por: Prandoni, Paolo, et al.
Publicado: (2011)

Acute on Chronic Venous Thromboembolism on Therapeutic Anticoagulation
por: Bassi, Byron, et al.
Publicado: (2013)

Pharmacology of anticoagulants used in the treatment of venous thromboembolism
por: Nutescu, Edith A., et al.
Publicado: (2016)

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism
por: Kim, Joo Hee, et al.
Publicado: (2017)

Apixaban for the treatment of cancer-associated venous thromboembolism and left atrial appendage thrombus refractory to optimal anticoagulation with warfarin: a case report
por: Koga, Masashi, et al.
Publicado: (2018)

Comparison of hospital length of stay in patients treated with non–vitamin K oral anticoagulants or parenteral agents plus warfarin for venous thromboembolism
por: Saint, Catherine A, et al.
Publicado: (2017)

Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization
por: Hohaus, Stefan, et al.
Publicado: (2018)

Identification of prophylaxis and treatment for hospitalized patients associated with venous thromboembolism
por: Yang, Yuanhua, et al.
Publicado: (2023)

Association between direct-acting oral anticoagulants vs. warfarin with the risk of osteoporosis in patients with non-valvular atrial fibrillation
por: Akhtar, Tauseef, et al.
Publicado: (2020)

Post-polypectomy bleeding and thromboembolism risks associated with warfarin vs direct oral anticoagulants
por: Yanagisawa, Naohiro, et al.
Publicado: (2018)

Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials
por: Frere, Corinne, et al.
Publicado: (2022)

Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Reply to author: “uric acid's influence on venous thromboembolism in East Asia”
por: Li, Haobo, et al.
Publicado: (2023)

Letter to the editor: “uric acid's influence on venous thromboembolism in East Asia”
por: Ji, Lixian, et al.
Publicado: (2023)

Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study
por: Khan, Adeel M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vc4jq4ifj5sbnpo87so0o3uerj